According to a study conducted in Japan, symptoms of smoking-related diseases may take several decades to appear, while alternative tobacco products have been introduced relatively recently. Therefore, there is no long-term epidemiological research, but real data can be used to attempt to find early signs of the impact of heated tobacco products (HTP) on public health.
From Japan to a city pilot in 2014, HTPs were launched nationwide in 2016 with the introduction of Philip Morris International's tobacco heating system. While overall tobacco sales have not shown a continuous decline, HTPs have led to a rapid decrease in cigarette sales. Two studies conducted in Japan, "The impact of the introduction of IQOS on cigarette sales: Evidence of decline and substitution" and "Why have cigarette sales declined rapidly in Japan?", were published in the Tobacco Control and International Journal of Environmental Research and Public Health in 2019 and 2020, respectively. These studies show that cigarette sales began to decrease significantly after the introduction of IQOS heating non-combustible products in 11 regions of Japan. The introduction of electronic cigarettes was staggered by region, and better predicted the timing of the decline in cigarette sales than any single model applied to all regions at the same time, adjusting for the actual month of introduction of IQOS heating non-combustible products in each region.
Another study attempted to determine whether the introduction of high technology procedures (HTP) in Japan is related to hospitalization rates for chronic obstructive pulmonary disease (COPD) and ischemic heart disease (IHD) worsening, showing a significant reduction in hospitalization rates for COPD worsening in Japan, although IHD hospitalization rates showed a slight decrease but were not significant.
A more comprehensive study was published in the June 2022 issue of the Journal of Public Health using the Japan Medical Data Center (JMDC) insurance claims database to replicate prior research, which included cumulative receipts and diagnoses for approximately 7.3 million patients. The study population included adults, corporate employees, and their family members who were hospitalized between January 2010 and December 2019. Analysis was conducted on full data from 2010 to 2019 and shorter-term data from 2013 to 2019, but no significant differences were found between the two periods.
According to an analysis conducted using data from the JMDC, the hospitalization rates for smoking-related illnesses have changed since the introduction of heated tobacco products. Specifically, when all available database data is used, hospitalization rates for chronic obstructive pulmonary disease and ischemic heart disease have significantly decreased. However, hospitalization rates for chronic obstructive pulmonary disease did not decrease significantly due to worsening of the condition and accompanying lower respiratory tract infections.
2FIRSTS will continue to provide coverage on this topic, with further updates available on the 2FIRSTS app. Scan the QR code below to download the app.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
